Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms

Completed · Not applicable

Conditions studied: Ovarian Neoplasms

In brief

This study will evaluate the expression of arginine vasopressin (AVP) by peptide and mRNA quantitation and also measurement of its V1 receptor mRNA, in the arteries and veins of ovarian malignant (cancerous) or benign (non-cancerous) tissue. The investigators will examine whether AVP protein and AVP and V1 receptor mRNA expression vary with respect to tumor histology, intratumoral vascularization and systemic blood pressure.

Key facts

Study ID

NCT00160472

Run by

United States Department of Defense

People needed

110

Starts

2004-03-01

Expected to finish

2009-01-01

Last updated by the study team

2010-02-26

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• All patients who have had gynecologic tissue removed for benign (noncancerous) or malignant (cancerous) indications.

You may not qualify if…

• Patients who have a malignancy that is not a primary gynecologic malignancy.
• Age less than 18
• Males

Where it is running

• Tripler Army Medical Center — Honolulu, Hawaii, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.